Platinum drugs – cisplatin and carboplatin – are among the most effective ovarian cancer treatments. But these drugs frequently damage the peripheral nerves, causing a condition called chemotherapy-induced peripheral neuropathy (CIPN). Research focused on gynecological malignancies shows that up to 36% of patients aged 70 and older who receive carboplatin plus paclitaxel develop grade 2 or higher neuropathy – meaning symptoms that interfere with daily activities. In patients under 70, the rate is around 20%. For many survivors, numbness, tingling, and burning pain persist long after the last infusion.
Curcumin – the main active ingredient in turmeric – has been studied for its nerve-protecting and anti-inflammatory properties. A 2025 double-blind randomized clinical trial assigned 70 adult cancer patients with established platinum-induced CIPN to receive either curcumin 40 mg twice daily or placebo for four weeks. By day 28, the curcumin group showed a statistically significant reduction in sensory symptom scores versus placebo (p = 0.021). This page explains what that evidence means, what it does not mean, and what to discuss with your care team.
| Feature | Cisplatin | Carboplatin |
|---|---|---|
| Primary neuropathy type | Predominantly sensory; affects hands and feet | Predominantly sensory; risk rises sharply when combined with paclitaxel |
| Relative neurotoxicity | Higher; considered the most neurotoxic platinum agent | Lower than cisplatin at standard doses |
| Incidence in ovarian cancer (grade 2 or higher neuropathy) | High; varies with cumulative dose | Approx. 20% in patients under 70; approx. 36% in patients aged 70 and older (carboplatin AUC 6 plus paclitaxel 175 mg/m2) |
| Onset pattern | During or shortly after treatment; continued worsening after final dose possible | During or after treatment; gradual onset typical |
| Long-term persistence | Can persist months to years; dose-dependent | Gradual improvement common but complete resolution unlikely in moderate to severe cases |
Incidence figures from PMC8223716 (gynecological cancer CIPN review). Neurotoxicity comparison from PMC3265255 (platinum analogue neurotoxicity review).
What Platinum Drugs Do to Peripheral Nerves
Cisplatin and carboplatin damage nerves by building up in the dorsal root ganglia – clusters of nerve cell bodies outside the spinal cord that send sensory signals from the limbs to the brain. A review of platinum analogue neurotoxicity explains that platinum drugs form stable chemical bonds (adducts) with nerve cell DNA, triggering cell death and gradual loss of sensation. Because carboplatin is used at higher doses in ovarian cancer and is often paired with paclitaxel (which also damages nerves), neuropathy rates are often higher than patients expect.
Recognizing Platinum Neuropathy Symptoms
Symptoms typically start at the tips of the fingers and toes and move inward over time. Common signs include:
- Numbness or reduced sensitivity to touch or temperature
- Tingling or a pins-and-needles sensation
- Burning pain, often worse at night
- Sensitivity to cold objects
- Difficulty with fine motor tasks such as buttoning clothing or picking up small items
- Balance problems or unsteady walking
Symptoms often appear during treatment and may continue to worsen for several weeks after the last dose – a pattern sometimes called coasting. A study of ovarian cancer patients found that neuropathy usually improves gradually after chemo ends, but probably won’t fully resolve if it was moderate to severe.
How Long Does Platinum Neuropathy Last?
Mild symptoms in many patients ease within a few months of finishing treatment. Moderate to severe neuropathy can persist for one to two years or longer. Long-term follow-up data in gynecological malignancies show that many patients still report significant neuropathy symptoms one to two years after their last platinum dose. Factors linked to slower recovery include older age, higher total platinum dose, pre-existing nerve damage, and poorly controlled blood sugar.
Tell your care team right away if you have neuropathy causing balance problems, trouble walking safely, or severe pain. Your oncologist may lower doses or delay treatment to prevent permanent nerve damage based on your overall treatment plan.
Where Curcumin Fits In
Curcumin is the main active ingredient in Curcuma longa (turmeric root). Research into its potential for nerve support focuses on two main mechanisms. First, curcumin blocks nuclear factor kappa B (NF-kB), a protein that drives pro-inflammatory cytokines – signaling molecules that keep nerve tissue inflamed. Laboratory research showed curcumin reduced NF-kB activation, lowered inflammatory molecules, and decreased nerve tissue damage from oxidation. Second, curcumin acts as an antioxidant, helping to neutralize the reactive oxygen species that platinum drugs generate and that contribute to nerve cell injury over time.
These mechanisms overlap with research on curcumin in other treatment-related pain conditions. If you have joint pain from aromatase inhibitors, read about aromatase inhibitor joint pain and curcumin dosing, which covers the same anti-inflammatory pathways.
What the Clinical Trial Found
A 2025 double-blind, randomized, placebo-controlled trial studied 70 adult cancer patients with established platinum-induced CIPN. Participants received curcumin 40 mg twice daily (80 mg per day total) or a matched placebo for four weeks. Researchers measured sensory symptom score changes using a standard neuropathy assessment tool.
At day 28, the curcumin group showed a statistically significant improvement in sensory symptom scores compared with the placebo group (p = 0.021). The authors noted no serious side effects in the curcumin group and called for larger, longer-duration trials to confirm and extend the finding. The trial was small, and four weeks is a short window for a condition that can last years. These limitations matter when weighing the evidence.
A separate trial tested nano-curcumin at 40 mg three times daily as a preventive measure in patients receiving FOLFOX or XELOX for colorectal cancer and did not find a benefit. This points to an important distinction: curcumin has evidence for managing existing neuropathy but has not been shown to prevent it during chemo. The effect also appears to differ by regimen and formulation. For related treatment strategies in colorectal cancer, the article on peripheral neuropathy after colorectal cancer chemo covers overlapping approaches.
Formulation and Bioavailability
Your body absorbs standard curcumin poorly. Most of an oral dose reaches the colon without entering systemic circulation in meaningful amounts. Enhanced formulations address this problem. A pilot bioavailability study showed that BCM-95 – which combines curcuminoids with turmeric essential oil – reaches higher blood levels than standard curcumin at the same dose. When you talk with your clinician about curcumin, ask what formulation they recommend and how well your body will absorb it. Oncostore’s BCM-95 Curcumin uses this sesquiterpenoid-enhanced approach for improved absorption. Note that the 2025 CIPN trial did not specify which formulation was used, so we don’t yet have published data comparing the trial product to BCM-95 absorption in these patients.
Safety and Drug Interactions
At the doses studied in the 2025 platinum CIPN trial – curcumin 40 mg twice daily for four weeks – researchers recorded no serious side effects. We don’t have much longer-term safety data at this dose in cancer patients. Key potential interactions to discuss with your oncologist include:
- Anticoagulants such as warfarin or low-molecular-weight heparin: curcumin might increase bleeding risk by thinning your blood.
- CYP3A4-metabolized drugs: high-dose curcumin may change how your liver breaks down chemotherapy agents or targeted therapies.
- Blood sugar-lowering medications: curcumin may lower glucose levels, which matters for patients taking metformin or insulin.
- PARP inhibitors: ovarian cancer maintenance therapy often includes olaparib or niraparib. We don’t yet know much about interactions with curcumin. The ovarian cancer PARP inhibitor side effects caregiver guide outlines the pharmacology of this drug class for useful background.
Building a Recovery Strategy
Think of curcumin as part of a larger approach to platinum neuropathy – it’s not a complete treatment by itself. Standard supportive options include physical therapy to improve balance and coordination, protective footwear to reduce fall risk, and (if pain is your main problem) talking with your oncologist about pain medications like duloxetine, which can help with nerve pain. Your doctor will check your vitamin B12 and folate levels, since low levels can make neuropathy worse. Keeping your blood sugar in target range also helps, since high blood sugar slows nerve healing.
You can browse Oncostore’s selection of nutraceuticals to compare different products and talk with your care team about which might work for you.
If you are currently taking prescription medications – including chemotherapy, targeted therapy, or PARP inhibitors – or if you are pregnant or breastfeeding, speak with a clinician before starting curcumin or any other supplement. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
